Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Zion Pharma.

    Client Virtual Booth

    ZION PHARMA

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Zion Pharma
    China Flag
    Country
    Country
    China
    Address
    Address
    Shanghai: Room 639, 6th Floor, Block C, No. 3, Lane 2889, Jinke Road, Pudong New Area, Shanghai
    Telephone
    Telephone
    021-20501736
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.zionpharma.com/sy
    Linkedin
    Linkedin
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Zion Pharma Announces Global Agreement with Roche to Develop and Commercialize a Blood Brain Barrier Penetrant Oral HER2 Tyrosine Kinase Inhibitor

    Details:

    Roche has acquired the global rights to Zion’s lead program, ZN-A-1041. ZN-A-1041 is an orally administered selective tyrosine kinase inhibitor targeting the Human Epidermal Growth Factor Receptor 2 (HER2).


    Lead Product(s): ZN-A-1041

    Therapeutic Area: Oncology Product Name: ZN-A-1041

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

    Deal Size: $680.0 million Upfront Cash: $70.0 million

    Deal Type: Acquisition May 09, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Zion Pharma Announces Initiation of Phase 1 Study

    Details:

    ZN-A-1041 is being developed to address the unmet medical need associated with brain metastases accompanying HER2+ advanced breast cancer.


    Lead Product(s): ZN-A-1041

    Therapeutic Area: Oncology Product Name: ZN-A-1041

    Highest Development Status: Phase IProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 08, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search